Breaking News

Enzene Announces Commercial Supply of Pertuzumab

Pertuzumab uses Enzene’s fully-connected continuous manufacturing (FCCM) technology.

Author Image

By: Charlie Sternberg

Associate Editor

Enzene has announced the commercial supply of pertuzumab, a monoclonal antibody (mAb) therapy indicated for the treatment of HER2-positive (HER2+) breast cancer. The product will be marketed in India by multiple pharmaceutical companies. Developed and scaled to commercial launch readiness at Enzene’s biologics facility in Pune, the product has received approval from the Drug Controller General of India (DCGI). Pertuzumab is the fourth mAb to reach commercial supply using Enzene’s proprietary ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters